CPX-351 vs standard chemo for certain adult AML types
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML (not AML that came back).
- Your AML does not have certain gene or chromosome changes (including t(15;17), t(8;21), inv(16), or t(16;16)).
- Your AML does not have these gene mutations: NPM1 and FLT3.
- You must be age 50 or older, and be well enough for treatment (ECOG 0–2).
- You should not have had prior chemo or radiation for another cancer (small exceptions for very limited use).
- You must not have active serious infections, hepatitis B/C, HIV, or known severe allergy to the study medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.